Indiplon: The development of a new hypnotic

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Indiplon is a short-acting hypnotic that is currently being developed as a treatment for insomnia by Neurocrine Biosciences and Pfizer, and is expected to be marketed in mid-2006. It is a high-affinity allosteric potentiator of GABAA responses that demonstrates preference for α1, subunit-containing GABAA receptors. Indiplon will be an addition to the general category of newer-generation hypnotics that now includes zaleplon, zolpidem, zopiclone and eszopiclone. Clinical trials were carried out with an immediate-release capsule and a modified-release tablet and demonstrate very positive efficacy and safety profiles. The major challenge will be developing a commercial success in the crowded insomnia treatment marketplace.

Original languageEnglish (US)
Pages (from-to)1269-1276
Number of pages8
JournalExpert Opinion on Investigational Drugs
Issue number10
StatePublished - Oct 1 2005


  • GABA receptors
  • Hypnotic
  • Indiplon
  • Insomnia
  • Modified release
  • Nonbenzodiazepine
  • Sleep disorders
  • α selective

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Indiplon: The development of a new hypnotic'. Together they form a unique fingerprint.

Cite this